|
1
|
Ingelfinger JR and Rosen CJ: Cardiac and
renovascular complications in type 2 diabetes-is there hope? N Engl
J Med. 375:380–382. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shulman GI: Ectopic fat in insulin
resistance, dyslipidemia, and cardiometabolic disease. N Engl J
Med. 371:1131–1141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nobécourt E, Tabet F, Lambert G, Puranik
R, Bao S, Yan L, Davies MJ, Brown BE, Jenkins AJ, Dusting GJ, et
al: Nonenzymatic glycation impairs the anti-inflammatory properties
of apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 30:766–772.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Younis NN, Soran H, Pemberton P,
Charlton-Menys V, Elseweidy MM and Durrington PN: Small dense LDL
is more susceptible to glycation than more buoyant LDL in Type 2
diabetes. Clin Sci (Lond). 124:343–349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Viney NJ, van Capelleveen JC, Geary RS,
Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke
RM, et al: Antisense oligonucleotides targeting apolipoprotein(a)
in people with raised lipoprotein(a): Two randomised, double-blind,
placebo-controlled, dose-ranging trials. Lancet. 388:2239–2253.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rye KA, Barter PJ and Cochran BJ:
Apolipoprotein A-I interactions with insulin secretion and
production. Curr Opin Lipidol. 27:8–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lehti M, Donelan E, Abplanalp W,
Al-Massadi O, Habegger KM, Weber J, Ress C, Mansfeld J, Somvanshi
S, Trivedi C, et al: High-density lipoprotein maintains skeletal
muscle function by modulating cellular respiration in mice.
Circulation. 128:2364–2371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fryirs MA, Barter PJ, Appavoo M, Tuch BE,
Tabet F, Heather AK and Rye KA: Effects of high-density
lipoproteins on pancreatic beta-cell insulin secretion.
Arterioscler Thromb Vasc Biol. 30:1642–1648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Duvillard L, Dautin G, Florentin E,
Jeannin A, de Barros JP Pais, Lagrost L, Petit JM, Gambert P and
Vergès B: Increased apolipoprotein AI production rate and
redistribution of high-density lipoprotein size induced by estrogen
plus progestin as oral contraceptive. J Clin Endocrinol Metab.
94:4891–4897. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bisoendial R, Tabet F, Tak PP, Petrides F,
Torres LF Cuesta, Hou L, Cook A, Barter PJ, Weninger W and Rye KA:
Apolipoprotein A-I limits the negative effect of tumor necrosis
factor on lymphangiogenesis. Arterioscler Thromb Vasc Biol.
35:2443–2450. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tabet F, Lambert G, Torres LF Cuesta, Hou
L, Sotirchos I, Touyz RM, Jenkins AJ, Barter PJ and Rye KA:
Lipid-free apolipoprotein A-I and discoidal reconstituted
high-density lipoproteins differentially inhibit glucose-induced
oxidative stress in human macrophages. Arterioscler Thromb Vasc
Biol. 31:1192–1200. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pu LJ, Lu L, Zhang RY, Du R, Shen Y, Zhang
Q, Yang ZK, Chen QJ and Shen WF: Glycation of apoprotein A-I is
associated with coronary artery plaque progression in type 2
diabetic patients. Diabetes Care. 36:1312–1320. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kollerits B, Krane V, Drechsler C, Lamina
C, März W, Ritz E, Wanner C and Kronenberg F: German Diabetes and
Dialysis Study Investigators: Apolipoprotein A-IV concentrations
and clinical outcomes in haemodialysis patients with type 2
diabetes mellitus-a post hoc analysis of the 4D Study. J Intern
Med. 272:592–600. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu A, Luo Y, Li T, Guo X, Ding X, Zhu X,
Wang X and Tang S: Low serum apolipoprotein A1/B ratio is
associated with proliferative diabetic retinopathy in type 2
diabetes. Graefes Arch Clin Exp Ophthalmol. 250:957–962. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Soriguer F, Garcia-Serrano S,
Garrido-Sánchez L, Gutierrez-Repiso C, Rojo-Martínez G,
Garcia-Escobar E, García-Arnés J, Gallego-Perales JL, Delgado V and
García-Fuentes E: Jejunal wall triglyceride concentration of
morbidly obese persons is lower in those with type 2 diabetes
mellitus. J Lipid Res. 51:3516–3523. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Galazis N, Afxentiou T, Xenophontos M,
Diamanti-Kandarakis E and Atiomo W: Proteomic biomarkers of type 2
diabetes mellitus risk in women with polycystic ovary syndrome. Eur
J Endocrinol. 168:R33–R43. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang W, Khan S, Blackett P, Alaupovic P
and Lee E: Apolipoproteins A-I, B, and C-III in young adult
Cherokee with metabolic syndrome with or without type 2 diabetes. J
Clin Lipidol. 7:38–42. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mendes-Lana A, Pena GG, Freitas SN, Lima
AA, Nicolato RL, Nascimento-Neto RM, Machado-Coelho GL and Freitas
RN: Apolipoprotein E polymorphism in Brazilian dyslipidemic
individuals: Ouro Preto study. Braz J Med Biol Res. 40:49–56. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Charriere S, Bernard S, Aqallal M, Merlin
M, Billon S, Perrot L, Le Coquil E, Sassolas A, Moulin P and
Marcais C: Association of APOA5-1131T>C and S19W gene
polymorphisms with both mild hypertriglyceridemia and
hyperchylomicronemia in type 2 diabetic patients. Clin Chim Acta.
394:99–103. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cabré A, Lázaro I, Girona J, Manzanares
JM, Marimón F, Plana N, Guardiola M, Heras M and Masana L: The
APOA5-1131 T>C variant enhances the association between RBP4 and
hypertriglyceridemia in diabetes. Nutr Metab Cardiovasc Dis.
20:243–248. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Celap I, Simundic AM, Nikolac N, Kackov S
and Katalinic D: Association of APOA5-1131T>C polymorphism and
serum lipid levels in patients with type 2 diabetes. DNA Cell Biol.
32:589–593. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sóter MO, Gomes KB, Fernandes AP, Carvalho
Md, Pinheiro PS, Bosco AA, Silva DD and Sousa MO: -1131T>C and
SW19 polymorphisms in APOA5 gene and lipid levels in type 2
diabetic patients. Mol Biol Rep. 39:7541–7548. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brito DD, Fernandes AP, Gomes KB, Coelho
FF, Cruz NG, Sabino AP, Cardoso JE, Figueiredo-Filho PP, Diamante
R, Norton CR and Sousa MO: Apolipoprotein A5-1131T>C
polymorphism, but not APOE genotypes, increases susceptibility for
dyslipidemia in children and adolescents. Mol Biol Rep.
38:4381–4388. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sørensen LP, Andersen IR, Søndergaard E,
Gormsen LC, Schmitz O, Christiansen JS and Nielsen S: Basal and
insulin mediated VLDL-triglyceride kinetics in type 2 diabetic men.
Diabetes. 60:88–96. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aslan I, Kucuksayan E and Aslan M: Effect
of insulin analog initiation therapy on LDL/HDL subfraction profile
and HDL associated enzymes in type 2 diabetic patients. Lipids
Health Dis. 12:542013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qin B, Anderson RA, Kuzuya T, Kitaura Y
and Shimomura Y: Multiple factors and pathways involved in hepatic
very low density lipoprotein-apoB100 overproduction in Otsuka
Long-Evans Tokushima Fatty rats. Atherosclerosis. 222:409–416.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hwang YC, Ahn HY, Kim WJ, Park CY and Park
SW: Increased apoB/A-I ratio independently associated with Type 2
diabetes mellitus: Cross-sectional study in a Korean population.
Diabet Med. 29:1165–1170. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pan J, Gao F, Bao Y, Zhang L, Tu Y and Jia
W: Non-high-density lipoprotein cholesterol is associated more
closely with albuminuria in Chinese type 2 diabetic patients with
normal renal function, compared with traditional lipid parameters.
J Clin Lipidol. 6:382–387. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vergès B, Guiu B, Cercueil JP, Duvillard
L, Robin I, Buffier P, Bouillet B, Aho S, Brindisi MC and Petit JM:
Retinol-binding protein 4 is an independent factor associated with
triglycerides and a determinant of very low-density
lipoprotein-apolipoprotein B100 catabolism in type 2 diabetes
mellitus. Arterioscler Thromb Vasc Biol. 32:3050–3057. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Taskinen MR, Barter PJ, Ehnholm C,
Sullivan DR, Mann K, Simes J, Best JD, Hamwood S and Keech AC:
FIELD study investigators: Ability of traditional lipid ratios and
apolipoprotein ratios to predict cardiovascular risk in people with
type 2 diabetes. Diabetologia. 53:1846–1855. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dahlén EM, Bjarnegard N, Länne T, Nystrom
FH and Ostgren CJ: Sagittal abdominal diameter is a more
independent measure compared with waist circumference to predict
arterial stiffness in subjects with type 2 diabetes-a prospective
observational cohort study. Cardiovasc Diabetol. 12:552013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chan DC, Wong AT, Yamashita S and Watts
GF: Apolipoprotein B-48 as a determinant of endothelial function in
obese subjects with type 2 diabetes mellitus: Effect of fenofibrate
treatment. Atherosclerosis. 221:484–489. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mancera-Romero J, Sánchez-Chaparro MA,
Rioja J, Ariza MJ, Olivecrona G, González-Santos P and Valdivielso
P: Fasting apolipoprotein B48 is a marker for peripheral arterial
disease in type 2 diabetes. Acta Diabetol. 50:383–389. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Béliard S, Nogueira JP, Maraninchi M,
Lairon D, Nicolay A, Giral P, Portugal H, Vialettes B and Valéro R:
Parallel increase of plasma apoproteins C-II and C-III in Type 2
diabetic patients. Diabet Med. 26:736–739. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Caron S, Verrijken A, Mertens I, Samanez
CH, Mautino G, Haas JT, Duran-Sandoval D, Prawitt J, Francque S,
Vallez E, et al: Transcriptional activation of apolipoprotein CIII
expression by glucose may contribute to diabetic dyslipidemia.
Arterioscler Thromb Vasc Biol. 31:513–519. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Onat A, Hergenc G, Ayhan E, Uğur M, Kaya
H, Tuncer M and Can G: Serum apolipoprotein C-III in high-density
lipoprotein: A key diabetogenic risk factor in Turks. Diabet Med.
26:981–988. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee SJ, Campos H, Moye LA and Sacks FM:
LDL containing apolipoprotein CIII is an independent risk factor
for coronary events in diabetic patients. Arterioscler Thromb Vasc
Biol. 23:853–858. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hiukka A, Stahlman M, Pettersson C, Levin
M, Adiels M, Teneberg S, Leinonen ES, Hultén LM, Wiklund O, Oresic
M, et al: ApoCIII-enriched LDL in type 2 diabetes displays altered
lipid composition, increased susceptibility for sphingomyelinase,
and increased binding to biglycan. Diabetes. 58:2018–2026. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Singh P, Singh M, Gaur S and Kaur T: The
ApoAI-CIII-AIV gene cluster and its relation to lipid levels in
type 2 diabetes mellitus and coronary heart disease: Determination
of a novel susceptible haplotype. Diab Vasc Dis Res. 4:124–129.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Onat A, Erginel-Unaltuna N, Coban N, Cicek
G and Yüksel H: APOC3-482C>T polymorphism, circulating
apolipoprotein C-III and smoking: Interrelation and roles in
predicting type-2 diabetes and coronary disease. Clin Biochem.
44:391–396. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
van Hoek M, van Herpt TW, Dehghan A,
Hofman A, Lieverse AG, van Duijn CM, Witteman JC and Sijbrands EJ:
Association of an APOC3 promoter variant with type 2 diabetes risk
and need for insulin treatment in lean persons. Diabetologia.
54:1360–1367. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dorfmeister B, Cooper JA, Stephens JW,
Ireland H, Hurel SJ, Humphries SE and Talmud PJ: The effect of
APOA5 and APOC3 variants on lipid parameters in European Whites,
Indian Asians and Afro-Caribbeans with type 2 diabetes. Biochim
Biophys Acta. 1772:355–363. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Smith CE, Tucker KL, Scott TM, Van Rompay
M, Mattei J, Lai CQ, Parnell LD, Junyent M, Lee YC, Garcia-Bailo B
and Ordovás JM: Apolipoprotein C3 polymorphisms, cognitive function
and diabetes in Caribbean origin Hispanics. PLoS One. 4:e54652009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lim W, Bae H and Song G: Differential
expression of apolipoprotein D in male reproductive system of rats
by high-fat diet. Andrology. 4:1115–1122. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dassati S, Waldner A and Schweigreiter R:
Apolipoprotein D takes center stage in the stress response of the
aging and degenerative brain. Neurobiol Aging. 35:1632–1642. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hansen L, Gaster M, Oakeley EJ, Brusgaard
K, Nielsen EM Damsgaard, Beck-Nielsen H, Pedersen O and Hemmings
BA: Expression profiling of insulin action in human myotubes:
Induction of inflammatory and pro-angiogenic pathways in
relationship with glycogen synthesis and type 2 diabetes. Biochem
Biophys Res Commun. 323:685–695. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Baker WA, Hitman GA, Hawrami K, McCarthy
MI, Riikonen A, Tuomilehto-Wolf E, Nissinen A, Tuomilehto J, Mohan
V, Viswanathan M, et al: Apolipoprotein D gene polymorphism: A new
genetic marker for type 2 diabetic subjects in Nauru and south
India. Diabet Med. 11:947–952. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Vijayaraghavan S, Hitman GA and Kopelman
PG: Apolipoprotein-D polymorphism: A genetic marker for obesity and
hyperinsulinemia. J Clin Endocrinol Metab. 79:568–570. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Miranda LF, Gomes KB, Tito PA, Silveira
JN, Pianetti GA, Byrro RM, Peles PR, Pereira FH, Santos TR, Assini
AG, et al: Clinical response to donepezil in mild and moderate
dementia: Relationship to drug plasma concentration and CYP2D6 and
APOE genetic polymorphisms. J Alzheimers Dis. 55:539–549. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Okamoto N, Morikawa M, Amano N, Yanagi M,
Takasawa S and Kurumatani N: Effects of tooth loss and the
apolipoprotein E ε4 Allele on mild memory impairment in the
Fujiwara-kyo study of Japan: A Nested Case-Control Study. J
Alzheimers Dis. 55:575–583. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Anthopoulos PG, Hamodrakas SJ and Bagos
PG: Apolipoprotein E polymorphisms and type 2 diabetes: A
meta-analysis of 30 studies including 5423 cases and 8197 controls.
Mol Genet Metab. 100:283–291. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tan KC, Shiu SW, Wong Y, Wong WK and Tam
S: Plasma apolipoprotein E concentration is an important
determinant of phospholipid transfer protein activity in type 2
diabetes mellitus. Diabetes Metab Res Rev. 22:307–312. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Reis KA, Ebinc FA, Koc E, Demirci H, Erten
Y, Güz G, Derici UB, Bali M, Söylemezoğlu O, Arınsoy T and Sindel
S: Association of the angiotensinogen M235T and APO E gene
polymorphisms in Turkish type 2 diabetic patients with and without
nephropathy. Ren Fail. 33:469–474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Monastiriotis C, Papanas N, Trypsianis G,
Karanikola K, Veletza S and Maltezos E: The ε4 allele of the APOE
gene is associated with more severe peripheral neuropathy in type 2
diabetic patients. Angiology. 64:451–455. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Al-Majed HT, Qasem JA, Al-Sherifi AK,
Al-Attar AA, Qasem AA and Abdullah SA: Association between
apolipoprotein E-polymorphism and Ischemic heart disease patients
with or without type 2 diabetes mellitus: A preliminary study in
Kuwait. Arch Iran Med. 14:385–388. 2011.PubMed/NCBI
|
|
56
|
Vaisi-Raygani A, Rahimi Z, Tavilani H and
Pourmotabbed T: Butyrylcholinesterase K variant and the APOE-ε4
allele work in synergy to increase the risk of coronary artery
disease especially in diabetic patients. Mol Biol Rep.
37:2083–2091. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chaudhary R, Likidlilid A, Peerapatdit T,
Tresukosol D, Srisuma S, Ratanamaneechat S and Sriratanasathavorn
C: Apolipoprotein E gene polymorphism: Effects on plasma lipids and
risk of type 2 diabetes and coronary artery disease. Cardiovasc
Diabetol. 11:362012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Winkler K, Hoffmann MM, Krane V, März W,
Drechsler C and Wanner C: Apolipoprotein E genotype predicts
cardiovascular endpoints in dialysis patients with type 2 diabetes
mellitus. Atherosclerosis. 208:197–202. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Irie F, Fitzpatrick AL, Lopez OL, Kuller
LH, Peila R, Newman AB and Launer LJ: Enhanced risk for Alzheimer
disease in persons with type 2 diabetes and APOE epsilon4: The
Cardiovascular Health Study Cognition Study. Arch Neurol. 65:89–93.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Dore GA, Elias MF, Robbins MA, Elias PK
and Nagy Z: Presence of the APOE epsilon4 allele modifies the
relationship between type 2 diabetes and cognitive performance: The
Maine-Syracuse Study. Diabetologia. 52:2551–2560. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kempf SJ, Janik D, Barjaktarovic Z,
Braga-Tanaka I III, Tanaka S, Neff F, Saran A, Larsen MR and Tapio
S: Chronic low-dose-rate ionising radiation affects the hippocampal
phosphoproteome in the ApoE-/-Alzheimer's mouse model. Oncotarget.
7:71817–71832. 2016.PubMed/NCBI
|
|
62
|
Zhang P, Gao J, Pu C, Feng G, Wang L,
Huang L, Tao Q and Zhang Y: Effects of hyperlipidaemia on plasma
apolipoprotein M levels in patients with type 2 diabetes mellitus:
An independent case-control study. Lipids Health Dis. 15:1582016.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhang H, Pluhackova K, Jiang Z and
Böckmann RA: Binding Characteristics of Sphingosine-1-Phosphate to
ApoM hints to assisted release mechanism via the ApoM
Calyx-opening. Sci Rep. 6:306552016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ooi EM, Watts GF, Chan DC, Nielsen LB,
Plomgaard P, Dahlbäck B and Barrett PH: Association of
apolipoprotein M with high-density lipoprotein kinetics in
overweight-obese men. Atherosclerosis. 210:326–330. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kurano M, Tsukamoto K, Hara M, Ohkawa R,
Ikeda H and Yatomi Y: LDL receptor and ApoE are involved in the
clearance of ApoM-associated sphingosine 1-phosphate. J Biol Chem.
290:2477–2488. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Qu X, Zhao S, Gao J, Hu M, Dong L and
Zhang X: Reduced expression and secretion of apolipoprotein M in
fat-fed, streptozotocin-diabetic rats is partially reversed by an
artificial ligand of PPARγ. Zhong Nan Da Xue Xue Bao Yi Xue Ban.
37:796–801. 2012.(In Chinese). PubMed/NCBI
|
|
67
|
Zhang PH, Gao JL, Pu C, Feng G, Wang LZ,
Huang LZ and Zhang Y: A single-nucleotide polymorphism C-724/del in
the proter region of the apolipoprotein M gene is associated with
type 2 diabetes mellitus. Lipids Health Dis. 15:1422016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhang PH, Gao JL, Pu C, Feng G, Wang L,
Huang L and Zhang Y: ApoM/HDL-C and apoM/apoA-I ratios are
indicators of diabetic nephropathy in healthy controls and type 2
diabetes mellitus. Clin Chim Acta. 466:31–37. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Niu N, Zhu X and Liu Y, Du T, Wang X, Chen
D, Sun B, Gu HF and Liu Y: Single nucleotide polymorphisms in the
proximal promoter region of apolipoprotein M gene (apoM) confer the
susceptibility to development of type 2 diabetes in Han Chinese.
Diabetes Metab Res Rev. 23:21–25. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zhang Z, Chu G and Yin RX: Apolipoprotein
M T-778C polymorphism is associated with serum lipid levels and the
risk of coronary artery disease in the Chinese population: A
meta-analysis. Lipids Health Dis. 12:1352013. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zhou JW, Tsui SK, Ng MC, Geng H, Li SK, So
WY, Ma RC, Wang Y, Tao Q, Chen ZY, et al: Apolipoprotein M gene
(APOM) polymorphism modifies metabolic and disease traits in type 2
diabetes. PLoS One. 6:e173242011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Guo H, Zhao XX, Zhang XJ, Chen W and Zhang
J: Functional study of −724I/D polymorphism in apolipoprotein M
(apoM) gene promoter region and its association with myocardial
infarction. Med Sci Monit. 21:371–375. 2015. View Article : Google Scholar : PubMed/NCBI
|
